Molecular Devices

ABACAVIR SULFATE

abacavir sulfate

Post-LOE

ORAL · TABLET

12.1 Mechanism of Action Abacavir is an antiretroviral agent [see ]. 12.3 Pharmacokinetics Pharmacokinetics in Adults The pharmacokinetic properties of abacavir were independent of dose over the range of 300 to 1,200 mg per day. Absorption Following oral administration, abacavir is rapidly absorbed and extensively distributed. The geometric mean absolute bioavailability of the tablet was 83%. Plasma abacavir AUC was similar following administration of the oral solution or tablets. After oral administration of 300 mg twice daily in 20 subjects, the steady-state peak serum abacavir concentration (C max ) was 3.0 ± 0.89 mcg per mL (mean ± SD) and AUC (0-12 h) was 6.02 ± 1.73 mcg•hour per mL. After oral administration of a single dose of 600 mg of abacavir in 20 subjects, C max was 4.26 ± 1.19 mcg per mL (mean ± SD) and AUC ∞ was 11.95 ± 2.51 mcg•hour per mL. Effect of Food Bioavailability of abacavir tablets was assessed in the fasting and fed states with no significant difference in systemic exposure (AUC ∞ ); therefore, abacavir tablets may be administered with or without food. Systemic exposure to abacavir was comparable after administration of abacavir oral solution and abacavir tablets. Therefore, these products may be used interchangeably. Distribution The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space. In 3 subjects, the CSF AUC (0-6 h) to plasma abacavir AUC (0-6 h) ratio ranged from 27% to 33%. Binding of abacavir to human plasma proteins is approximately 50% and was independent of concentration. Total blood and plasma drug-related radioactivity concentrations are identical, demonstrating that abacavir readily distributes into erythrocytes. Elimination In single-dose trials, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours. After intravenous administration, total clearance was 0.80 ± 0.24 L per hour per kg (mean ± SD). Metabolism In humans, abacavir is not significantly metabolized by cytochrome P450 enzymes. The primary routes of elimination of abacavir are metabolism by alcohol dehydrogenase to form the 5′-carboxylic acid and glucuronyl transferase to form the 5′-glucuronide. The metabolites do not have antiviral activity. In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations. Excretion Elimination of abacavir was quantified in a mass balance trial following administration of a 600-mg dose of C-abacavir: 99% of the radioactivity was recovered, 1.2% was excreted in the urine as abacavir, 30% as the 5′-carboxylic acid metabolite, 36% as the 5′-glucuronide metabolite, and 15% as unidentified minor metabolites in the urine. Fecal elimination accounted for 16% of the dose. Specific Populations Patients with Renal Impairment The pharmacokinetic properties of abacavir have not been determined in patients with impaired renal function. Renal

Should You Work at Molecular Devices?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (242)

Key Products by Revenue

Other Products (231)

Open Jobs (1321)

Occupational Health Nurse

Senior Research Executive

Purchasing Coordinator

Scientist

Market Development Manager - Biopharma

Senior Director Quality Operations

Danaher Business System Specialist

Senior Commercial Financial Analyst

Technician Production Operations

Technician Production Operations (Tech Ops)

Senior Engineer, Process Validation

Senior Cybersecurity Risk Analyst - USA Remote

Client Engagement Executive (Healthcare Consultant), Performance Partnership - REMOTE

Regional Marketing Manager - Americas

Lead Software Engineer I (DevOps, Azure, SQL, Nifi/ Dagster)

Service Sales Specialist, Pune

Field Service Engineer - Seattle, WA

Danaher Business System Leader, Marketing (Continuous Improvement Leader)

Commercial Danaher Business System Leader, North America (Continuous Improvement Leader)

Field Service Engineer - Daily Field Travel – Buffalo, NY Territory (necessity to reside within 60 minutes of Buffalo or ability to relocate)

Area Sales Manager - Distribution Sales (Central US)

Sr. Production Associate I (Manufacturing): D-Shift (7:00pm-7:00am Thurs. PM-Sun. AM, and every other Wed. PM-Thurs. AM)

Senior Financial Analyst, Functions-Bangalore

Technical Application Specialist - Clinical Microbiology- Chicago and Surrounding Regions

Maintenance Technician I - 1st Shift

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)